The long Avandia endgame

Lancet. 2011 Jul 9;378(9786):113. doi: 10.1016/s0140-6736(11)61071-4.
No abstract available

Publication types

  • News

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy
  • Drug Approval / legislation & jurisprudence*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use
  • Product Surveillance, Postmarketing
  • Rosiglitazone
  • Thiazolidinediones / adverse effects*
  • Thiazolidinediones / therapeutic use
  • United Kingdom
  • United States
  • United States Food and Drug Administration*

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone